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ABSTRACT
OBJECTIVE
To evaluate differences in downstream testing, 
coronary revascularisation, and clinical outcomes 
following non-invasive diagnostic modalities used to 
detect coronary artery disease.
DESIGN
Systematic review and network meta-analysis.
DATA SOURCES
Medline, Medline in process, Embase, Cochrane 
Library for clinical trials, PubMed, Web of Science, 
SCOPUS, WHO International Clinical Trials Registry 
Platform, and Clinicaltrials.gov.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Diagnostic randomised controlled trials comparing  
non-invasive diagnostic modalities in patients 
presenting with symptoms suggestive of low risk 
acute coronary syndrome or stable coronary artery 
disease.
DATA SYNTHESIS
A random effects network meta-analysis synthesised 
available evidence from trials evaluating the 
effect of non-invasive diagnostic modalities 
on downstream testing and patient oriented 
outcomes in patients with suspected coronary 
artery disease. Modalities included exercise 
electrocardiograms, stress echocardiography, 
single photon emission computed tomography-
myocardial perfusion imaging, real time myocardial 
contrast echocardiography, coronary computed 
tomographic angiography, and cardiovascular 
magnetic resonance. Unpublished outcome data 
were obtained from 11 trials.
RESULTS
18 trials of patients with low risk acute coronary 
syndrome (n=11 329) and 12 trials of those with 
suspected stable coronary artery disease (n=22 062) 
were included. Among patients with low risk acute 
coronary syndrome, stress echocardiography, 
cardiovascular magnetic resonance, and exercise 
electrocardiograms resulted in fewer invasive 
referrals for coronary angiography than coronary 
computed tomographic angiography (odds ratio 
0.28 (95% confidence interval 0.14 to 0.57), 0.32 
(0.15 to 0.71), and 0.53 (0.28 to 1.00), respectively). 
There was no effect on the subsequent risk of 
myocardial infarction, but estimates were imprecise. 
Heterogeneity and inconsistency were low. In patients 
with suspected stable coronary artery disease, an 
initial diagnostic strategy of stress echocardiography 
or single photon emission computed tomography-
myocardial perfusion imaging resulted in fewer 
downstream tests than coronary computed 
tomographic angiography (0.24 (0.08 to 0.74) and 
0.57 (0.37 to 0.87), respectively). However, exercise 
electrocardiograms yielded the highest downstream 
testing rate. Estimates for death and myocardial 
infarction were imprecise without clear discrimination 
between strategies.
CONCLUSIONS
For patients with low risk acute coronary 
syndrome, an initial diagnostic strategy of stress 
echocardiography or cardiovascular magnetic 
resonance is associated with fewer referrals for 
invasive coronary angiography and revascularisation 
procedures than non-invasive anatomical testing, 
without apparent impact on the future risk of 
myocardial infarction. For suspected stable coronary 
artery disease, there was no clear discrimination 
between diagnostic strategies regarding the 
subsequent need for invasive coronary angiography, 
and differences in the risk of myocardial infarction 
cannot be ruled out.
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WhAT iS AlReAdy knoWn on ThiS TopiC
Information on diagnostic accuracy is important for decisions on the usefulness 
of a diagnostic test, which might not translate into patient benefits
Diagnostic randomised controlled trials provide the most conclusive evidence 
regarding patient outcomes, and represent a rigorous approach to diagnostic 
test evaluation
Several non-invasive imaging modalities can be used to investigate patients with 
suspected low risk acute coronary syndromes or stable coronary artery disease, 
but their effect on downstream testing and clinical outcomes remains unknown 
and inconsistent
WhAT ThiS STudy AddS
In patients with low risk acute coronary syndrome, functional testing (stress 
echocardiography and cardiovascular magnetic resonance) is associated with 
fewer referrals for downstream invasive coronary angiography than coronary 
computed tomographic angiography, without apparent impact on subsequent 
risk of myocardial infarction
Among patients with suspected stable coronary artery disease, functional testing 
(stress echocardiography and single photon emission computed tomography-
myocardial perfusion imaging) is associated with less requirement for additional 
diagnostic investigations (overall downstream testing) than coronary computed 
tomographic angiography, although the estimates cannot rule out a significant 
effect on the risk of myocardial infarction associated with individual tests
Future adequately powered clinical trials should evaluate more broadly 
defined clinical outcomes, subsequent use of hospital resources, and cost 
effectiveness aspects of implemented strategies, which are representative of 
current clinical practice
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introduction
Chest pain is a leading cause for physician consultation 
that leads to several million office and emergency 
department visits as well as hospital admissions 
yearly.1  2 Despite the use of clinical decision rules3-5 
and the improved sensitivity of cardiac biomarkers,6-8 
many patients who are admitted to the emergency 
department in order to exclude an acute coronary 
syndrome are ultimately found not to have a cardiac 
cause of their symptoms. Conversely, patients with 
symptoms who undergo cardiac investigations because 
of chest pain and are diagnosed with non-cardiac 
causes or in whom the cause of chest pain remains 
undetermined are at increased risk of subsequent 
cardiovascular events and death.9 10
Guidelines published in 2012 by the American 
College of Cardiology Foundation/American Heart 
Association recommended the use of functional 
testing, mainly on the basis of evidence derived 
from studies of diagnostic accuracy (because the 
vast majority of diagnostic randomised trials were 
published after these guidelines).11 However, recent 
audits in large numbers of patients showed only a 
modest effect on subsequent diagnostic findings.12 
Currently, functional and anatomical non-invasive 
tests are widely available and used according to 
locally available resources and expertise (box): 
exercise electrocardiograms, single photon emission 
computed tomography (CT)-myocardial perfusion 
imaging, stress echocardiography, real time 
myocardial contrast echocardiography, coronary 
CT angiography, and cardiovascular magnetic 
resonance. Among these, coronary CT angiography 
as the only non-invasive anatomical diagnostic 
modality has been suggested to overcome limitations 
of traditional functional testing and has undergone 
close scrutiny in recent years.13 14 So far, diagnostic 
randomised controlled trials do not provide 
conclusive evidence as to whether a non-invasive 
anatomical or functional testing strategy gives the 
best results for subsequent downstream testing or 
clinical outcomes. Therefore, we summarised the 
available evidence and evaluated clinical endpoints 
of different non-invasive diagnostic modalities in 
patients with symptoms suggestive of coronary artery 
disease through network meta-analysis.
Methods
The detailed protocol that follows the template of a 
Cochrane review for multiple interventions is available 
in PROSPERO registry (CRD42016049442),15 and was 
prepared according to the guidelines of the Cochrane 
Multiple Interventions Methods Group.16
Data sources and searches
We performed a broad literature search in Medline, 
Medline in process, Embase, Cochrane Library for 
clinical trials, PubMed, Web of Science, SCOPUS, WHO 
International Clinical Trials Registry Platform, and 
Clinicaltrials.gov (appendix 1). A search algorithm was 
developed and adapted for each database, without 
language or sample size restrictions.
Box: Key features of widely used functional and anatomical tests for non-invasive diagnosis of coronary artery disease
Exercise electrocardiograms
This test aims to detect myocardial ischaemia indirectly through electrocardiographic changes during exercise and recovery, which is the 
physiological consequence of a mismatch between myocardial oxygen supply (coronary blood flow) and myocardial oxygen demand (myocardial 
work). It is a well validated tool for the assessment of functional capacity and chronotropic response to exercise.
Stress echocardiography
Cardiac ultrasound (echocardiography) is used to evaluate myocardial function (contractility) at rest, and during exercise or pharmacological 
stress. It can detect the presence and extent of coronary artery disease by provoking regional ischaemia with resulting wall motion abnormalities. 
Myocardial ischaemia is provoked either by exercise (treadmill or bicycle) or pharmacological agents (predominantly dobutamine).
Real time myocardial contrast echocardiography
This test uses an intravenous echocardiographic contrast agent during stress echocardiography. While echo-contrast agents can be used to 
improve endocardial border definition in patients with suboptimal echocardiographic images, they also allow visualisation of myocardial tissue 
perfusion.
Single photon emission computed tomography-myocardial perfusion imaging
This technique uses intravenous administration of a radioactive myocardial perfusion tracer (radioisotope) to evaluate cardiac perfusion and 
function at rest and during dynamic exercise or pharmacological stress. The technique provides information on the presence or absence of 
myocardial ischaemia, myocardial infarction (and viability), and ventricular function.
Coronary computed tomographic angiography
This test allows direct visualisation of the coronary artery lumen and wall using an intravenous contrast agent to produce a computed tomographic 
coronary angiogram. Preceding non-contrast scans can assess the presence and extent of coronary artery calcium in the vessel wall, which is a 
marker of extent of coronary atherosclerosis and future risk, but not necessarily related to the severity of coronary artery narrowing.
Stress cardiovascular magnetic resonance imaging
This advanced cross sectional imaging procedure acquires two or three dimensional images of the heart. Using a contrast agent during 
pharmacological stress, first pass perfusion images can be used to identify areas of low myocardial blood flow (ischaemia) or stress induced 
regional wall motion abnormalities. During a single study, information is also provided on regional or global resting ventricular function, 
myocardial infarction (and viability), and proximal coronary artery anatomy.
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Study selection
We included diagnostic randomised controlled trials 
comparing any non-invasive anatomical (evaluation 
of coronary anatomy) or functional (detection of 
myocardial ischaemia) diagnostic strategy for the 
detection of coronary artery disease in patients 
without previously known coronary artery disease but 
presenting with symptoms suggestive of low risk acute 
coronary syndrome or stable coronary artery disease. 
Low risk acute coronary syndrome was defined as 
patients typically presenting with chest pain (or 
anginal equivalent) for at least 5 minutes at rest within 
the past 24 hours, without history of known coronary 
artery disease, without diagnostic ischaemic changes 
on electrocardiogram, without haemodynamic or 
clinical instability, and an initial troponin level lower 
than the 99th percentile of the used assay. These 
patients typically do not need immediate assessment 
by invasive coronary angiography. 
We also considered trials comparing any diagnostic 
strategy with a standard of care as defined by the 
authors, and trials that allowed in the same arm any 
diagnostic test of the same testing group (that is, 
functional testing). We included trials in which at least 
one comparative pair non-invasive diagnostic tests was 
available, irrespective of the number of trial arms. As a 
condition, we consider that within each patient group, 
any of the diagnostic approaches could have been 
applied and hence they can be considered “jointly 
randomiseable.”17
Data extraction and quality assessment
Characteristics of trials, patients, and diagnostic 
strategies, were summarised. Details of the extracted 
items are available in the online protocol. Following 
the index diagnostic strategy, we considered as primary 
endpoints the subsequent referral to invasive coronary 
angiography and any coronary revascularisation. We 
considered the rate of invasive coronary angiography 
as an indicator of downstream testing, and the rate of 
revascularisation as surrogate for clinically significant 
coronary artery disease. Downstream testing is the 
need for additional diagnostic investigations that are 
performed (invasive or non-invasive (or both)) after the 
initial diagnostic test or strategy. Typically, this might 
occur after test failure or diagnostic uncertainty in 
relation to the index test result. 
The outcome parameters were chosen on the basis 
of the hypothesis that a non-invasive, anatomically 
driven strategy might be more sensitive to identify 
non-clinically significant coronary artery disease 
(as suggested by previous studies), which in turn 
could have a prognostic effect.18 19 We also collected 
information on patient oriented outcomes (myocardial 
infarction and death), and overall downstream testing 
(including the number of additional diagnostic tests 
after the index diagnostic intervention during follow-
up). In case of missing outcomes in the main and 
subsequent publications of the included trials, we 
contacted the principal investigator of each trial to 
provide additionally required information.
We evaluated the internal validity of the trials by 
using the Cochrane risk of bias tool.20 Each item 
was described as being at low, high, or unclear risk 
of bias for random sequence generation, allocation 
concealment, blinding (participants/personnel and 
outcomes), incomplete outcome data, and selective 
outcome reporting. We evaluated the risk of bias in 
each trial and pairwise comparison overall for the 
outcome of referral to invasive coronary angiography 
as low, moderate, or high risk of bias, based on our 
judgments for allocation concealment and blinding of 
outcome assessment.
Data synthesis and analysis
We performed the predefined analyses separately for 
each group of study population as defined according 
to clinical presentation, and for each outcome 
according to established meta-analytical methods.21 22 
The detailed analysis plan is available in PROSPERO 
(CRD42016049442). Study specific odds ratios were 
synthesised by use of random effects pairwise and 
network meta-analysis.23-27 A treatment hierarchy was 
obtained according to ranking probabilities summarised 
with the surface under the cumulative ranking curve.28 
We estimated a common heterogeneity by using restricted 
maximum likelihood and evaluated its magnitude by 
comparing the estimated variance (𝜏2) to its empirical 
distribution for pharmacological interventions and 
semiobjective outcomes. According to the empirical 
distribution, the median is 0.04 (interquartile range 
0-1.58).29 Estimates around 0.04, 0.16, and 0.36 can 
be considered to represent a low, moderate, and high 
degree of heterogeneity, respectively.30 To evaluate the 
assumption of consistency,31 we compared the direct 
and indirect evidence within each loop of evidence32 and 
used a design by treatment test.33 In case of important 
heterogeneity or inconsistency, we planned to explore 
sources using potential effect modifiers as described in 
the protocol, but this was not possible owing to the low 
number of trials. 
In primary analyses, we considered each individual 
diagnostic strategy separately as applied in each 
trial. Two trials, CRESCENT34 and PROMISE,35 
randomised patients to an anatomical versus a 
functional diagnostic strategy using functional tests 
that are widely available in clinical practice (exercise 
electrocardiograms, stress echocardiography, and 
single photon emission CT-myocardial perfusion 
imaging). For the primary analysis, these trials were 
assigned as having randomised the patients to exercise 
electrocardiograms34 and to single photon emission 
CT-myocardial perfusion imaging,35 which were the 
most frequently used tests in each trial. 
In secondary analyses, we grouped traditional 
functional tests in a single node and compared them 
with coronary CT angiography as a purely anatomical 
test and cardiovascular magnetic resonance as an 
advanced imaging modality. Cardiovascular magnetic 
resonance was not included in the node of functional 
tests because of the different nature and availability of 
this advance imaging modality. This merging of tests 
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is expected to increase the power of the analysis.36 
Finally, we did a sensitivity analysis by excluding the 
two trials34 35 that did not randomise the patients to an 
individual diagnostic strategy.
We calculated numbers needed to treat and numbers 
needed to harm for each outcome and each group 
of patients after grouping for functional testing as 
mentioned above, by applying the estimated odds 
ratios and confidence intervals to the odds of events 
estimated in patients randomly allocated to an 
anatomical based strategy (coronary CT angiography). 
For this purpose, we considered a baseline risk based 
on the event rates in the ACRIN-PA37 38 and PROMISE35 
trials for patients presenting with low risk acute 
coronary syndrome and suspected of stable coronary 
artery disease, respectively. Both trials were the largest 
in each group of patients (low risk acute coronary 
syndrome and stable coronary artery disease) and 
examined the role of an anatomical testing strategy.
Analyses were performed in Stata (network 
and network graph packages).39 To illustrate the 
assessments of risk of bias for the primary outcome of 
referral to invasive coronary angiography, we produced 
a bar graph showing how much information came 
from high, moderate, and low risk of bias trials for 
each network estimate by using CINeMA (Confidence 
in Network Meta-Analysis) software.40 We assessed the 
effect of study limitations in all network meta-analysis 
estimates using graphs based on the contribution 
matrix.31
Patient involvement
No patients were involved in the development of the 
research question, development of outcome measures, 
design, or conduct of this study. No patients were 
asked to advise on interpretation or writing up of 
results. There are no plans to involve patients in the 
dissemination of the results of this study.
Results
Our search yielded 19 674 citations, which were 
initially screened on abstract level for eligibility; 101 
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Fig 1 | Network plots of examined diagnostic strategies across different patient groups. Network plots show 
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reports were retrieved and reviewed in full text. Finally, 
30 diagnostic randomised controlled trials (34 reports) 
including 33 391 patients (16 083 women) and six 
different imaging modalities were deemed eligible 
(box, fig 1, appendices 1 and 2). Appendix 3 shows 
the diagnostic accuracy of the evaluated imaging 
modalities based on previously published studies 
(appendix 4 lists abbreviations used). Figure 2 shows 
the diagnostic pathways chosen following the index 
diagnostic intervention across the trials. Descriptive 
details of the included trials and resulting networks are 
provided in table 1, figure 1, and appendix 5.
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The final list of diagnostic strategies in each graph refer to downstream tests performed after the index diagnostic 
strategy. *Information on downstream testing is missing from one trial. ICA=invasive coronary angiography; 
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Eligible trials included patients with low risk acute 
coronary syndrome (18 trials, 11 329 patients)37 38 
41-59 and suspected stable coronary artery disease 
(12 trials, 22 062 patients34 35 60-70; table 1). The 
recruitment period for most of the trials was completed 
during the last 10 years. Seven trials reported industry 
related funding, 17 obtained exclusively non-industry 
funding, and six disclosed no funding. Fifteen 
trials were multicentre and two included three arm 
comparisons. In only three41 43 46 trials of patients with 
low risk acute coronary syndrome, the authors clarified 
the use of a high sensitive troponin assay. A diagnostic 
strategy based on the recommended standard of care 
was included in 11 trials on acute coronary syndrome 
and two on stable coronary artery disease. Appendix 
5 provides event rates for each assessed outcome 
parameter. We obtained unpublished outcome data 
from 11 trials34 35 41 42 44 56 57 61-63 66 by contacting the 
principal investigators.
Most trials were considered to be at low risk in five 
of the assessed areas of potential bias, whereas no trial 
blinded the participants and personnel to the allocated 
diagnostic interventions (appendix 6). One trial43 was 
judged to be at high risk of bias related to random 
sequence generation and allocation concealment, 
one44 was considered high risk in relation to the 
blinding of outcome assessment, and one51 had 
possible incomplete data reporting. The risk of bias 
was frequently unclear, owing to limited reporting 
in the publications. Appendix 6 details the results of 
the risk of bias assessment and the contribution of 
comparisons with low, moderate, and high risk of bias 
to each network meta-analysis estimate.
Comparative efficacy of non-invasive diagnostic 
strategies
Patients with low risk acute coronary syndrome
Patients initially evaluated by stress echocardiography, 
cardiovascular magnetic resonance, or exercise 
electrocardiograms to exclude coronary artery disease 
among patients with low risk acute coronary syndrome 
were less likely to be referred to invasive coronary 
angiography compared with coronary CT angiography 
(odds ratio 0.28 (95% confidence 0.14 to 0.57), 0.32 
(0.15 to 0.71), and 0.53 (0.28 to 1.00), respectively). 
However, differences were marginal for single photon 
emission CT-myocardial perfusion imaging (0.78 (0.58 
to 1.03)) and standard of care (0.85 (0.69 to 1.05)) 
compared with coronary CT angiography (fig 1A, fig 3). 
Heterogeneity was low (𝜏2=0.023; fig 3, appendix 7). 
Table 1 | Diagnostic randomised controlled trials and characteristics
Trial first author,  
publication year Recruitment period Source of funding
No of  
centres Comparisons
Sample 
size
Low risk acute coronary syndrome
BEACON,41 2016 July 2011-January 2014 Non-industry 7 CCTA v standard care 500
Levsky et al,42 2015 July 2008-March 2012 Non-industry 1 CCTA v SPECT-MPI 400
CT-COMPARE,43 2014 March 2010-April 2011 Non-industry 1 CCTA v exercise ECG 562
CATCH,44 45 2013 January 2010-January 2013 Industry related 1 CCTA v standard care 600
Lim et al,46 2013 August 2000-May 2002 Non-industry 1 SPECT-MPI v standard care 1690
Miller et al,47 2013 2011 Non-industry 1 CMR v standard care 105
ROMICAT-II,48 2012 April 2010-January 2012 Non-industry 9 CCTA v standard care 1000
ACRIN-PA,37 38 2012 July 2009-November 2011 Non-industry 5 CCTA v standard care 1392
CT-STAT,49 2011 June 2007-November 2008 Industry related 16 CCTA v SPECT-MPI 749
Miller et al,50 2011 October 2008-February 2009 Non-industry 1 CCTA v standard care 60
Miller et al,51 52 2010 January 2008-April 2009 Non-industry 1 CMR v standard care 109
Nucifora et al,53 2009 Not reported None reported 10 Stress echo v exercise ECG v standard care 290
Chang et al,54 2008 May 2006-February 2007 None reported 1 CCTA v standard care 266
Goldstein et al,55 2007 March 2005-September 2005 Industry related 1 CCTA v standard care 197
Jeetley et al,56 2007 January 2003-April 2004 Non-industry 1 Stress echo v exercise ECG 433
Nucifora et al,57 2007 Not reported None reported 10 Stress echo v exercise ECG 199
Jeetley et al,58 2006 Not reported None reported 1 Stress echo v exercise ECG 302
Udelson et al,59 2002 July 1997-May 1999 None reported 7 SPECT-MPI v standard care 2475
Stable coronary artery disease
IAEA-SPECT/CTA,60 2016 June 2011-June 2014 Non-industry 6 CCTA v SPECT-MPI 303
CE-MARC 2,61 2016 November 2012-March 2015 Non-industry 6 CMR v SPECT-MPI v standard care 1202
CRESCENT,34 2016 April 2011-July 2013 Non-industry 4 CCTA v functional testing* 350
Zacharias et al,62 2016 February 2013-March 2014 None reported 1 Stress echo v exercise ECG 385
PROMISE,35 2015 July 2010-September 2013 Non-industry 193 CCTA v functional testing* 10 003
SCOT-HEART,63 64 2015 November 2010-September 2014 Non-industry 12 CCTA v standard care 4146
Laiq et al,65 2015 October 2007-October 2011 Industry related 1 RTMCE v stress echo 1649
CAPP,66 2015 September 2010-November 2011 Non-industry 2 CCTA v exercise ECG 500
Porter et al,67 2013 October 2007-December 2011 Non-industry 1 RTMCE v stress echo 2063
Min et al,68 2012 December 2008-June 2009 Industry related 2 CCTA v SPECT-MPI 180
WOMEN,69 2011 Not reported Industry related 43 SPECT-MPI v exercise ECG 824
Sabharwal et al,70 2007 February 2001-July 2002 Industry related 1 SPECT-MPI v exercise ECG 457
Trials ordered chronologically, starting from most recently published trial. ECG=electrocardiogram; echo=echocardiography; RTMCE=real time myocardial contrast echocardiography;  
SPECT-MPI=single photon emission computed tomography-myocardial perfusion imaging; CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic resonance.
*Functional testing includes exercise electrocardiograms, stress echocardiography, or single photon emission computed tomography-myocardial perfusion imaging, as has been defined in 
individual trials.
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Initial evaluation by coronary CT angiography 
yielded more frequent downstream invasive coronary 
angiography and ranked as the diagnostic strategy 
resulting in most referrals to invasive coronary 
angiography. There was no evidence of inconsistency 
(P=0.64). Most of the evidence contributing to these 
treatment effects was based on low to moderate risk of 
bias (appendix 6).
Patients evaluated by cardiovascular magnetic 
resonance were less likely to undergo revascularisation 
than those assessed by stress echocardiography 
(ranked as first and second diagnostic strategies, 
respectively). Fewer revascularisation procedures were 
observed among patients who were initially evaluated 
by cardiovascular magnetic resonance, single photon 
emission CT-myocardial perfusion imaging, or the 
standard care than by coronary CT angiography (odds 
ratio 0.17 (95% confidence 0.04 to 0.65), 0.57 (0.41 
to 0.79), and 0.68 (0.53 to 0.88), respectively; fig 3), 
with consistent findings between direct and indirect 
evidence.
Despite the differences between the diagnostic 
modalities in referrals for invasive coronary 
angiography and revascularisation, none of the 
strategies affected the rate of subsequent myocardial 
infarction, although the derived estimates were not 
precise. In terms of overall downstream testing, all 
diagnostic strategies (apart from cardiovascular 
magnetic resonance) were statistically significant 
better than a standard of care approach, which resulted 
in the highest rate of downstream testing (appendix 7). 
Significant disagreement between direct and indirect 
estimates was not identified, but heterogeneity was 
high (𝜏2=1.21).
After grouping of widely available functional 
tests (including exercise electrocardiograms, stress 
echocardiography, or single photon emission CT-
myocardial perfusion imaging; fig 1B), a functional 
testing strategy and cardiovascular magnetic 
resonance were less likely than an anatomical testing 
(coronary CT angiography) strategy to lead to referrals 
for invasive coronary angiography (odds ratio 0.71 
(95% confidence interval 0.53 to 0.96) and 0.32 (0.15 
to 0.72), respectively; 𝜏2=0.032; fig 4, appendix 8). 
Considering overall downstream testing, a functional 
testing strategy was ranked first but without significant 
difference compared with an anatomical testing 
strategy. For both outcomes of downstream testing 
and myocardial infarction, the derived estimates were 
imprecise.
Table 2 presents the estimated numbers needed 
to treat to prevent one event and numbers needed 
to harm to cause one event for different outcomes 
after grouping of functional diagnostic strategies. 
For example, in the comparison of functional testing 
versus anatomical testing in terms of risk of myocardial 
infarction, the number needed to harm was 133. The 
95% confidence interval indicated that results were 
compatible with both a beneficial effect of a strategy 
based on functional versus anatomical testing, 
resulting in a number needed to treat to prevent one 
event of 194 or more. The confidence interval also 
indicated that results were compatible with a harmful 
effect of functional testing, resulting in a number 
needed to harm to cause one event of 25 or more.
Patients with suspected stable coronary artery 
disease
Seven individual non-invasive diagnostic strategies 
were examined and constitute the network of patients 
with symptoms assessed for suspected stable coronary 
artery disease (fig 1C). For the outcomes of invasive 
coronary angiography referral and revascularisation, 
no individual diagnostic strategy differed from an 
anatomical strategy (coronary CT angiography), apart 
from single photon emission CT-myocardial perfusion 
imaging that marginally yielded less invasive coronary 
angiography (odds ratio 0.54 (95% confidence interval 
0.30 to 0.98)) and subsequent revascularisations 
(0.57 (0.37 to 0.87); fig 5). There was no evidence 
Invasive coronary angiography
  Stress echo
  CMR
  Exercise ECG
  SPECT-MPI
  Standard care
Heterogeneity: τ2=0.023
Any revascularisation
  Stress echo
  CMR
  Exercise ECG
  SPECT-MPI
  Standard care
Heterogeneity: τ2<0.001
Downstream testing
  Stress echo
  CMR
  Exercise ECG
  SPECT-MPI
  Standard care
Heterogeneity: τ2=1.21
Myocardial infarction
  Stress echo
  CMR
  Exercise ECG
  SPECT-MPI
  Standard care
Heterogeneity: τ2<0.001
0.28 (0.14 to 0.57)
0.32 (0.15 to 0.71)
0.53 (0.28 to 1.00)
0.78 (0.58 to 1.03)
0.85 (0.69 to 1.05)
0.44 (0.16 to 1.24)
0.17 (0.04 to 0.65)
0.56 (0.21 to 1.49)
0.57 (0.41 to 0.79)
0.68 (0.53 to 0.88)
0.27 (0.04 to 1.67)
2.87 (0.32 to 25.9)
0.69 (0.14 to 3.44)
0.60 (0.12 to 2.98)
4.11 (1.74 to 9.74)
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Fig 3 | Νetwork meta-analysis effects of examined individual diagnostic strategies 
versus coronary computed tomographic angiography (anatomical testing), for study 
group of patients with low risk acute coronary syndrome. Forest plot considers 
individual diagnostic strategies, as shown in figure 1A. Index test indicates any 
diagnostic modality other than coronary computed tomographic angiography 
(anatomical testing). Network meta-analysis for the outcome of death was not 
feasible because of missing data and zero events. ECG=electrocardiogram; 
echo=echocardiography; SPECT-MPI=single photon emission computed tomography-
myocardial perfusion imaging; CCTA=coronary computed tomographic angiography; 
CMR=cardiovascular magnetic resonance
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of inconsistency (P=0.62) and heterogeneity was 
moderate to high (𝜏2=0.336) for referrals to invasive 
coronary angiography. Overall, downstream testing 
favoured an initial diagnostic strategy with stress 
echocardiography (0.24 (0.08 to 0.74)) or single 
photon emission CT-myocardial perfusion imaging 
(0.57 (0.37 to 0.87)), but not cardiovascular magnetic 
resonance (0.95 (0.41 to 2.22)) compared with 
coronary CT angiography (fig 5, appendix 9). Exercise 
electrocardiograms were ranked last, with the highest 
rate of downstream testing compared with any other 
diagnostic strategy. The overall heterogeneity was 
moderate (τ2=0.137). 
We detected inconsistency in the loop of coronary CT 
angiography, exercise electrocardiograms, and single 
photon emission CT-myocardial perfusion imaging, 
which was also verified with the sidesplit approach 
(P=0.48 for the inconsistency model overall). In the 
main analysis, we did not obtain a clear discrimination 
for most of the individual diagnostic strategies 
(imprecise estimates with broad confidence intervals 
and visually flat rankograms) for the clinical outcomes 
of myocardial infarction and death (fig 5, appendix 9).
In pairwise meta-analysis, functional testing 
resulted in fewer referrals for invasive coronary 
angiography (odds ratio 0.65 (95% confidence 
interval 0.58 to 0.74), τ2<0.001) than non-invasive 
anatomical testing (coronary CT angiography), with 
a similar estimate (0.63 (0.44 to 0.90)) from network 
meta-analysis after grouping of the functional tests 
(fig 1D). Cardiovascular magnetic resonance ranked 
first with regards to fewer referrals for invasive 
coronary angiography (with an estimate of 0.37 (0.19 
to 0.72)) compared with standard of care in indirect 
comparisons (appendix 10), although with detectable 
inconsistency (P<0.05 in sidesplit approach). In the 
network of strategies, functional testing resulted in 
fewer revascularisation procedures than anatomical 
testing (0.57 (0.41 to 0.78); fig 6), and this finding 
was consistent between direct and indirect evidence 
with low heterogeneity (τ2=0.029). Despite differences 
in referrals for invasive assessment and subsequent 
revascularisation, no statistical significant difference 
was observed for the outcome of myocardial infarction 
for patients who were initially evaluated with a 
functional or anatomical based strategy (appendix 
10). However, there was a trend towards favouring an 
anatomical testing strategy (fig 6).
In a sensitivity analysis excluding two trials 
(CRESCENT34 and PROMISE35) that randomised 
the patients to a non-specific functional test, the 
obtained estimates did not allow for any clear 
discrimination between the individual diagnostic 
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Fig 4 | Νetwork meta-analysis effects of examined grouped diagnostic strategies versus 
coronary computed tomographic angiography (anatomical testing), for study group 
of patients with low risk acute coronary syndrome. Forest plot considers grouping of 
functional tests, as shown in figure 1B. Index test indicates any diagnostic modality 
other than coronary computed tomographic angiography (anatomical testing). Network 
meta-analysis for the outcome of death was not feasible because of missing data and 
zero events. CCTA=coronary computed tomographic angiography; CMR=cardiovascular 
magnetic resonance
Table 2 | Estimated numbers needed to treat (NNT) and numbers needed to harm (NNH) for assessed outcomes in network meta-analysis for anatomical 
versus functional testing. Data in brackets are 95% confidence intervals
Baseline 
risk†
Functional testing v 
anatomical testing
Cardiovascular magnetic resonance v 
anatomical testing
Standard care v 
anatomical testing
Low risk acute coronary syndrome‡
Invasive coronary angiography* 7.4 NNT 49 (NNT 30 to NNT 364) NNT 20 (NNT 16 to NNT 51) NNT 96 (NNT 45 to NNH 210)
Downstream testing* 43.6 NNT 8 (NNT 3 to NNH 6) NNH 4 (NNT 4 to NNH 2) NNH 3 (NNH 7 to NNH 2)
Any revascularisation 3.0 NNT 79 (NNT 58 to NNT 155) NNT 40 (NNT 35 to NNT 97) NNT 106 (NNT 72 to NNT 285)
Myocardial infarction 1.3 NNH 133 (NNT 194 to NNH 25) NNH 52 (NNT 110 to NNH 5) NNH 196 (NNT 432 to NNH 58)
Stable coronary artery disease§
Invasive coronary angiography* 12.2 NNT 24 (NNT 16 to NNT 92) NNT 20 (NNT 12 to NNH 73) NNH 19 (NNT 92 to NNH 7)
Downstream testing* 21.2 NNH 35 (NNT 14 to NNH 6) NNH 11 (NNT 8 to NNH 2) NNH 12 (NNT 11 to NNH 3)
Any revascularisation 6.2 NNT 39 (NNT 28 to NNT 77) NNT 106 (NNT 32 to NNH 40) NNT 74 (NNT 36 to NNH 173)
Myocardial infarction 0.6 NNH 480 (NNT 1289 to NNH 155) NNH 102 (NNT 523 to NNH 19) NNH 255 (NNT 16766 to NNH 95)
Death 1.5 NNT 6767 (NNT 250 to NNH 189) NNH 1129 (NNT 93 to NNH 24) NNH 252 (NNT 217 to NNH 52)
*Estimated for procedures up to three months.
†Risk of events in patients receiving coronary computed tomographic angiography.
‡Baseline risk is based on event rates of ACRIN-PA trial.37 38
§Baseline risk is based on event rates of PROMISE trial.35
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strategies (appendix 11). By comparison of functional 
with anatomical testing in terms of risk of myocardial 
infarction, the number needed to harm was 480. The 
95% confidence interval indicated that results were 
compatible with a beneficial effect of a strategy based 
on functional compared with anatomical testing, 
resulting in a number needed to treat to prevent one 
event of 1289 or more. The confidence interval also 
indicated that results were compatible with a harmful 
effect of functional testing, resulting in a number 
needed to harm to cause one event of 155 or more 
(table 2).
discussion
Main findings
This study assesses the available evidence derived from 
diagnostic randomised controlled trials of strategies 
to detect coronary artery disease in a systematic and 
comprehensive way in two different clinical settings. 
Firstly, among patients with low risk acute coronary 
syndrome not required to undergo early invasive 
assessment, initial functional testing in terms of 
stress echocardiography or cardiovascular magnetic 
resonance was most strongly associated with a 
reduction of referrals for downstream invasive coronary 
angiography and revascularisation procedures, 
compared with anatomical testing using coronary CT 
angiography. No diagnostic strategy had an apparent 
effect on the subsequent risk of myocardial infarction, 
although estimates were imprecise.
Secondly, among patients with symptoms 
suggestive of stable coronary artery disease, no clear 
discrimination was seen across individual diagnostic 
strategies for the primary outcome of invasive coronary 
angiography referrals, mainly because of the limited 
number of trials contributing to each comparison. Stress 
echocardiography and single photon emission CT-
myocardial perfusion imaging resulted in less overall 
downstream testing than coronary CT angiography, 
whereas exercise electrocardiograms required the 
most further downstream testing. After grouping of 
widely available functional tests, a functional testing 
approach yielded fewer referrals for invasive coronary 
angiography and subsequent revascularisations than 
anatomical testing. Again, estimates were imprecise 
for the outcome of myocardial infarction, and any 
differences could not be ruled out.
Implications for patients with low risk acute 
coronary syndrome
Among patients with suspected acute coronary 
syndrome without relevant electrocardiographic 
changes and negative biomarkers, several different 
non-invasive modalities have been tested in trials to 
detect clinically relevant coronary artery disease. In 
this clinical setting, coronary CT angiography has 
shown high sensitivity and negative predictive value, 
although the positive predictive value using invasive 
coronary angiography as reference standard has been 
shown to be moderate.71 72
In our meta-analysis, a diagnostic strategy based 
on anatomical testing with use of coronary CT 
angiography was associated with increased referral 
rates for downstream invasive coronary angiography 
and revascularisation, some of which could have 
occurred in the absence of evidence of ischaemia. 
High sensitivity troponin assays, which were used in a 
minority of the included trials in our meta-analysis, are 
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Fig 5 | Νetwork meta-analysis effects of examined individual diagnostic strategies 
versus coronary computed tomographic angiography (anatomical testing), for study 
group of patients with stable coronary artery disease. Forest plot consider individual 
diagnostic strategies, as shown in figure 1C. Index test indicates any diagnostic 
modality other than coronary computed tomographic angiography (anatomical 
testing). Real time myocardial contrast echocardiography was not included in the 
network meta-analysis for outcome of downstream testing because of unavailable 
data. ECG=electrocardiogram; echo=echocardiography; RTMCE=real time myocardial 
contrast echocardiography; SPECT-MPI=single photon emission computed tomography-
myocardial perfusion imaging; CCTA=coronary computed tomographic angiography; 
CMR=cardiovascular magnetic resonance
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currently available and negative test results can serve 
as an efficient gatekeeper of unnecessary downstream 
diagnostic testing in this group of patients. However, 
non-coronary diseases might also cause elevated levels 
of high sensitivity troponin and subsequently subject 
patients with low pretest probability for coronary artery 
disease to unnecessary interventions. Therefore, the 
selection of patients with a higher pretest probability 
presenting in the emergency department, the definition 
of higher initial cutoff values, and the focus on dynamic 
changes over time are key points of the appropriate 
diagnostic testing in this clinical setting by increasing 
the positive predictive value of high sensitivity cardiac 
troponin.73 In our analysis, the rate of clinical events 
was low and our estimates are therefore imprecise for 
risk estimates of myocardial infarction, and with wide 
95% confidence intervals, cannot rule out relevant 
increases or reductions in the risk of myocardial 
infarction associated with functional testing.
Economic resources are becoming more constrained 
while healthcare demands are increasing in this 
clinical setting. Therefore, it is important to assess the 
comparative effectiveness of such diagnostic strategies 
not only in terms of safety and diagnostic accuracy, 
but also in terms of efficiency and cost. To this effect, 
we found no difference in rates of overall downstream 
testing between anatomical and functional based 
strategies, while a standard of care approach was the 
strategy with the highest rates of downstream testing. 
This result could be attributed to the fact that doctors 
make the final decision to refer patients for further 
invasive testing on the basis of factors other than initial 
non-invasive imaging, such as clinical presentation, 
persistence of symptoms, repeated clinical encounters, 
and patient preference.74 75 A functional testing 
strategy might provide important cost benefits, owing 
to fewer referrals for invasive coronary angiography 
and revascularisation and lower radiation and contrast 
agent exposure while resulting in similar clinical 
outcomes.76 Such benefits could reduce healthcare 
expenditure in this common clinical scenario in 
appropriately selected patients with low risk acute 
coronary syndrome. However, the availability and 
rapid access to functional imaging modalities (such as 
stress echocardiography or cardiovascular magnetic 
resonance) in the acute coronary syndrome setting 
might be limited.
Implications for patients with suspected stable 
coronary artery disease
For outpatients with suspected stable angina, our 
comprehensive synthesis of diagnostic randomised 
controlled trials indicates that an initial strategy based 
on functional testing might be preferable, resulting in 
fewer referrals for invasive coronary angiography and 
revascularisation. However—as was the case for the 
group with acute coronary syndrome—our estimates 
for the risk of myocardial infarction and death were 
imprecise, and wide 95% confidence intervals again 
cannot rule out relevant increases or reductions in the 
risk of myocardial infarction or death associated with 
functional testing. 
Guidelines published in 2012 by the American 
College of Cardiology Foundation/American Heart 
Association recommend functional testing as the initial 
strategy.11 However, a concurrent use of functional and 
anatomical testing has been proposed on the basis of 
findings from two landmark trials (PROMISE35 and 
SCOT-HEART63 64) that evaluated the role of coronary 
CT angiography in patients with suspected stable 
coronary artery disease.77 Our results agree with 
these guidelines, but contradict the recently updated 
guidelines from the National Institute for Health 
and Care Excellence (NICE). The NICE guidelines 
advise a non-invasive anatomical approach (coronary 
CT angiography) as first line diagnostic strategy 
with subsequent functional testing only in case of 
inconclusive results of the initial diagnostic test, 
without considering the individual pretest probability 
of coronary artery disease.78
In a nationwide cohort study,79 Jorgensen and 
colleagues found a diagnostic approach based on 
non-invasive anatomical testing to be associated 
with modifications to cardiovascular related drug 
treatments, increased downstream invasive coronary 
testing and subsequent revascularisation, and a lower 
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Fig 6 | Νetwork meta-analysis effects of examined grouped diagnostic strategies versus 
coronary computed tomographic angiography (anatomical testing), for study group 
of patients with stable coronary artery disease. Forest plot considers grouping of 
functional tests, as shown in figure 1D. Index test indicates any diagnostic modality 
other than coronary computed tomographic angiography (anatomical testing). 
CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic 
resonance
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risk of myocardial infarction (hazard ratio 0.71, 95% 
confidence interval 0.61 to 0.82) compared with 
functional testing. Similarly, a conventional meta-
analysis including three trials in the corresponding 
analysis showed a borderline significant reduction of 
myocardial infarction with coronary CT angiography 
compared with a mixture of functional testing and 
standard care (odds ratio 0.69 (95% confidence 
interval 0.49 to 0.98)).80
In our network meta-analysis, we found a statistically 
non-significant signal of a similar magnitude. Results 
in figure 6 correspond to an odds ratio of myocardial 
infarction of 0.74 favouring coronary CT angiography 
over functional testing (95% confidence interval 0.48 
to 1.15). However, our network meta-analysis made 
full use of all available evidence from 12 randomised 
trials comparing seven different diagnostic strategies 
within one analysis, appropriately quantifying the 
uncertainty of hard clinical outcomes associated with 
these strategies. Nevertheless, both the direction and 
magnitude of effects in our analysis are comparable 
with the large cohort study by Jorgensen and 
colleagues79 and the conventional meta-analysis.80
A decrease in the risk of subsequent myocardial 
infarction related to an anatomical testing strategy 
is indeed possible and cannot be ruled out based 
on our results. However, whether intensification of 
medical treatment (primary or secondary prevention) 
or the increased rate of subsequent coronary 
revascularisation (or both) affect the prognosis of 
patients undergoing coronary CT angiography remains 
unknown. Finally, the baseline risk of myocardial 
infarction in the landmark PROMISE trial35 and the 
cohort study by Jorgensen and colleagues79 were low 
(0.6% and 0.8% for up to one month, respectively). 
This resulted in absolute risk differences between 
functional testing and coronary CT angiography of 
about 0.2%, with a corresponding number needed to 
harm around 500 for this outcome (table 2), which is 
arguably irrelevant to raise safety concerns.
Implications for clinicians, policymakers, and other 
researchers
Diagnostic tests are critical components of an effective 
healthcare system. Diagnostic randomised controlled 
trials should become the default evaluation tool for 
new imaging modalities and clinical outcomes.81-83 
Our systematic evaluation show that the low event 
rates have resulted in sample sizes of thousands of 
patients in recent trials but without allowing for a 
clear discrimination between the individual diagnostic 
strategies. Along the same lines, the use of broader 
clinical (composite) endpoints might be clinically 
meaningful in future trials. More importantly, 
the resulting networks of trials suggest that each 
technological innovation became the standard 
for subsequent future trials (that is, coronary CT 
angiography), although no clear advantage in terms 
of clinical outcomes had been shown compared with 
previous diagnostic strategies. Future adequately 
powered clinical trials should aim to clarify the 
differential effects on more broadly defined clinical 
outcomes (which could occur during longer follow-up 
periods), and subsequent use of hospital resources and 
cost effectiveness aspects of implemented strategies, 
which are representative of current clinical practice.
Currently, there is a broad range of non-invasive 
imaging modalities to investigate patients with 
suspected low risk acute coronary syndrome or stable 
coronary artery disease, with further studies required 
to determine how to best integrate these tests in the 
patient care pathway. Several parameters such as 
locally available technology and expertise, patient’s 
preferences, and relevant contraindications for each 
test should be taken into account when deciding on the 
appropriate imaging modality. Any potential benefits 
of the applied diagnostic test should be carefully 
evaluated in the context of its risks (that is, radiation 
exposure for coronary CT or invasive coronary 
angiography).
Study limitations
This study had several limitations. Firstly, access to 
individual patient data that would have allowed us 
to identify potential differential effects in specific 
subgroups of patients was not available. Secondly, 
the low event rate of clinical outcomes (such as 
myocardial infarction and death) reflective of low risk 
populations and the sparse data for some comparisons 
(that is, those informed only by one trial) might have 
not provided enough power to clearly discriminate 
diagnostic strategies, especially within the stable 
coronary artery disease group. Thirdly, information 
on cost effectiveness as part of the downstream testing 
among the identified strategies was not given in most 
of the individual studies; therefore, we were not able to 
evaluate this aspect. Fourthly, the primary endpoints of 
invasive coronary angiography and revascularisation 
is partly attributed to physician judgment, which is 
not the case for the patient oriented outcomes of death 
and myocardial infarction. Finally, the standard of 
care, which was often a comparator in our study, has 
substantially evolved over the years. Earlier trials might 
not be directly relevant to present practice. However, 
the vast majority of the studies had been conducted in 
the past decade, and no differences during that period 
or compared with present practice are expected to have 
affect the results.
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